Peroxiredoxins as potential targets for cardiovascular disease
Thats a big deal, especially when you think about obesity as a risk factor for so many chronic illnesses. Drawing on nationally representative U.S
Safety, Tolerability, and Proof-of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats
Studies show patients who manage nausea well and remain on stable doses achieve the same or better weight loss outcomes as those with more severe side effects
Adjustment for age, parity, ethnicity, income, occupation, education and preexisting comorbidity did not alter the findings substantially (adjusted HR 0.96 [95% CI 0.83-1.12]), nor did the sensitivity analyses produce results that supported a significant association
This raises hope that retatrutide might help patients achieve weight loss on the order of 2530% or more if given for a longer duration a level previously seen only with bariatric surgery